Press releases
These press releases are intended for journalists and analysts/investors.
-
GSK recalls from trade two batches of Children’s Panadol® 1-5 years Suspension
GSK is working with the Therapeutic Goods Administration (TGA) to recall two batches of Children’s Panadol® 1-5 years Suspension
-
New medicine listed on the PBS for the treatment of metastatic melanoma in Australia
The listing of Tafinlar® (dabrafenib mesilate) on the Pharmaceutical Benefits Scheme (PBS) will lead to improved access to the medicine
-
URGENT SAFETY ALERT - Syringe Dosing Device for Children’s Panadol
GlaxoSmithKline (GSK) is initiating a recall of Children’s Panadol Baby Drops Syringe dosing device due to possible inaccurate placement
-
GSK award shines light on seismic change to epilepsy diagnosis
GSK has awarded Professor Ingrid Scheffer the 2013 GlaxoSmithKline Award for Research Excellence (ARE) for helping to transform
-
GSK Adult Immunisation Grants 2013
Four projects set to increase adult immunisation rates across Australia have received funding through the GSK 2013 Adult Immunisation Grants
-
Monash-GSK pharmaceutical partnership wins two prestigious National B-HERT Collaboration Awards
GSK Australia’s manufacturing R & D team and the Monash Institute of Pharmaceutical Sciences (MIPS) received two industry awards
-
TGA listing of Trobalt® (retigabine)
The Therapeutic Goods Administration (TGA) has registered Trobalt (retigabine)
-
SYDNEY BUSHFIRES: Access to Emergency Asthma Medication
GlaxoSmithKline (GSK), Asthma Foundation NSW and the Pharmacy Guild of Australia are working in partnership to provide asthma rescue
-
Asthma Patients Breathe New Life Into Old Puffers
More than 600,000 asthma sufferers across Victoria are set to breathe a little more easily knowing their old puffers will no longer
-
PROLIA® (denosumab) now approved for the treatment of osteoporosis in men
Amgen Australia and GlaxoSmithKline Australia (GSK) today announced the Therapeutic Goods Administration (TGA) has approved a new indication
-
Australian Medicine Icon is Back!
New Children’s Panadol® 1-5 Years Suspension Now on Shelf
-
GSK awards grant for Indigenous researcher at University of Melbourne
GlaxoSmithKline (GSK) Australia will award a capacity building grant to an Indigenous researcher from The University of Melbourne's School
-
Poppy Crop Security
GlaxoSmithKline (GSK) is aware that there may be an increased concern in poppy crop security from recent media reports in Tasmania
-
Tafinlar® (dabrafenib mesilate) registered for the treatment of metastatic melanoma in Australia
Tafinlar® (dabrafenib) has been approved by the Therapeutics Goods Administration (TGA) in Australia for the treatment of patients
-
Update to Rotarix prescribing information
GlaxoSmithKline Australia (GSK) has updated the prescribing information (PI) for Rotarix®, its rotavirus vaccine
-
GSK to Trial Poppy Growing in Victoria
GlaxoSmithKline (GSK) Australia announced today that small scientific trials of poppies, used as a source of medicinal alkaloids
-
Children’s Panadol® 1-5 Years Suspension temporarily out of stock
The makers of Children’s Panadol®, GSK, today confirmed that their Children’s Panadol® 1-5 years suspension range would be out of stock
-
Update on dosing device in new Children’s Panadol 1-5 years suspension
GlaxoSmithKline (GSK) is disappointed with the decision made on Wednesday 17 July 2013 by the Federal Court to grant a temporary injunction
-
Dosing device in new Children’s Panadol 1-5 years suspension
GlaxoSmithKline (GSK) is disappointed with the decision made on May 28 2013 by the Federal Court (Justice Rares)
-
New GSK additions to the National Immunisation Program (NIP)
The addition of two new vaccines to the National Immunisation Program means that Australian children will now require two less injections
